Responses
E-Poster viewings
Trials in Progress
IGCS19-0383
393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.